Wed, Aug 27, 2014, 6:33 AM EDT - U.S. Markets open in 2 hrs 57 mins

Recent

% | $
Quotes you view appear here for quick access.

BIOLASE, Inc. Message Board

  • imastockpimp imastockpimp Dec 19, 1998 4:43 PM Flag

    Re-visiting this msg boardh

    I sure am glad I dumped this dog many months ago. You boys keep hanging on.

    I might jump back in around $1. Ha Ha!

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • BIOLASE TECHNOLOGY Announces Market Introduction
      of New Diode Laser Millennium Sales Ramping Up

      Wednesday, December 23, 1998 08:31 AM Mail this article to a
      friend new!

      SAN CLEMENTE, Calif.--(BW
      HealthWire)--Dec. 23, 1998--BIOLASE TECHNOLOGY, INC. (NASDAQ
      SmallCap - BLTI) today announced the addition of the Diode
      laser to its market leading dental product line. The
      diode laser has emerged to be a highly respected and
      coveted tool in today's dental
      practice.

      Commenting about the BIOLASE LD-15 diode system, Dr. David
      S. Hornbrook, DDS, FAACD, and Director of P.A.C.
      Live at the University of Pacific, San Francisco; "If
      I had to name one instrument in my office that has
      taken my aesthetic practice to the next level, it would
      be the LD-15 diode laser." Dr. Hornbrook further
      commented, "I have tried other diode lasers in the past, but
      none compare to the design and usability...It (BIOLASE
      LD-15) stands head and shoulders above any
      competition."


      There have been extensive studies showing the diode,
      and particularly the advanced BIOLASE LD-15, to be
      effective for many clinical applications. Dr. Andreas
      Moritz, at the University of Vienna, along with Dr.
      Gutknecht at Aachen University, have used the LD-15 as the
      standard for their research on the clinical efficacy of
      the diode laser. Moritz and Gutknecht have found the
      laser to be very effective for many soft tissue
      procedures as well as bacteria reduction.


      BIOLASE
      has commenced sales, with several of the new laser
      systems shipping immediately. The retail price of the new
      diode system is $24,000.00. Jeffrey W. Jones, newly
      appointed President and CEO of BIOLASE, remarked "This new
      product has won the respect and acceptance of leading
      dentists. The diode laser, as a soft tissue laser, is a
      strategically sound addition, to the newly approved hard tissue
      Millennium(tm). Having both systems further strengthens BIOLASE's
      position in the dental market."


      Further
      commenting, Jones stated "This month, December 1998, BIOLASE
      will also begin to reap the benefits of its new and
      historical FDA clearance for laser based HydroKinetic(tm)
      patented technology. The Millennium(tm) hard tissue
      HydroKinetic(tm) laser system is unprecedented. Market reception
      is strong. We are establishing very key
      relationships and, most significantly, realizing revenue with a
      big increase in current month
      shipments."


      BIOLASE Technology, Inc. manufactures and markets
      advanced cosmetic, aesthetic, dental and surgical
      products, including laser systems, HydroKinetic(tm)
      surgical cutting systems and other laser and non-laser
      based products for the professional and home consumer
      markets. The Company's products incorporate patented and
      patent-pending technologies that permit achieving results in
      unique ways.


      The matters discussed in this
      news release include forward-looking statements which
      are subject to various risks, uncertainties and other
      factors that could cause actual results to differ
      materially from the results anticipated in such
      forward-looking statements. Such risks, uncertainties and other
      factors include, but are not limited to, the effect of
      actions of third parties, including governmental
      officials, the timely development and acceptance of new
      products, the impact of competitive products and pricing,
      and other risks detailed from time-to-time in the
      Company's filings with the Securities and Exchange
      Commission, including the reports on Forms 10-K and 10-Q.
      These forward-looking statements represent the
      Company's judgment as of the date of this release. The
      Company disclaims, however, any intent or obligation to
      update these forward-looking statements.




      CONTACT: BIOLASE Technology, Inc. Jeffrey W. Jones,
      949/361-1200 or Pacific Consulting Group, Inc. Scott Liolios,
      949/574-3860

      Quote for referenced ticker symbols: BLTI


      � 1998, Business Wire

    • "Ha Ha!" was the most intelligent part if this message. Congratulations!

      Amiga2000C

      • 1 Reply to Amiga2000C
      • I am just as long on this as you but it is hard
        to remain confident in this when nasdaq is at all
        time high, going up 40 and 50 points a day and this
        one keeps dropping. It would be nice if we heard
        something encouraging from management. But they remain
        silent to us, the shareholders. I'm hoping that they
        have something in the works like a takeover, or
        selling laserbrush unit and don't want to say anything to
        screw it up.

    • Know what? Short BLTI! I'll borrow you my shares. You don't have to believe today. You'll KNOW in 12 months.

      regards
      Amiga2000C

    • InPhilTrader,

      I fully agree. This is the
      most negative aspect. A few cheap lasers don't hurt
      BLTI, but this move is an indication for slow adoption
      of this new technology. But hey, we have to deal
      with dentists!
      The latest comments from Biolase
      were much more positive than this PLSIA press
      release.

      regards
      Amiga2000C

    • Just look back over the past two years. Lots of
      promises, no delivery. Co. has had approval for several
      products for a long time yet no sales. This means Co.
      can't produce or no one wants to buy. Same answer, NO
      SALES. Sales are ramping up this qtr.; when you are
      coming from zero even one unit sale is ramping up.This
      is simply a valuation issue. Even at $2. stock is
      over valued, IMO.

    • did BLTI receive FDA approval because there is no reference to it in the announcement?

    • PLSIA built excess inventory for Henry Schein and
      had (and still has) a dispute with them shortly
      thereafter. What the price reduction actually tells us is
      that those lasers don't sell (fast enough) at the $45k
      level. Of course Collette can't put it this way, but
      this is how I read it.
      In the end those lasers
      won't affect BLTI very much since this market is in its
      infant stage and BLTI's success is not dependent on a
      small number of discounted lasers. A broad acceptance
      for alternatives to the high speed drill must develop
      among dentists. If this doesn't happen, both Centauri
      and Millennium won't be a succeess. But when it
      really happens, there's plenty of room for
      both.

      regards
      Amiga2000C

    • Wrong. Stock is undervalued. And you will have to
      agree soon. Millenniums will sell like they never did
      since now there are three new markets (Canada, Italy,
      US). Additionally BLTI will deliver against backlog
      from Germany. So the Millennium alone will provide
      significant revenues in 1H/99.
      But this is no the whole
      story. Watch out for the LaserToner to generate a nice
      portion to revenues, too. This is a completely new
      product with a very good opportunity to revolutionize its
      market place. If you had the choice between CO2 and
      LaserToner, I bet even you'd chose the latter.
      Today BLTI
      announces another new product. "BIOLASE has commenced
      sales, with several of the new laser systems shipping
      immediately. The retail price of the new diode system is
      $24,000.00."
      BTW: Do you remember what we had to pay for a 20 MB
      hard disk in 1988? New technology is expensive and its
      price will come down throughout the years. Same with
      Biolase products.

      -> Very intersting patents,
      FDA market clearances, new and innovative products


      -> excellent takeover target.

      -> Stock
      extremely undervalued


      Amiga2000C

    • cedar,

      maybe you should read this one:
      "Further commenting, Jones stated "This month, December
      1998, BIOLASE will also begin to reap the benefits of
      its new and historical FDA clearance for laser based
      HydroKinetic(tm) patented technology. The Millennium(tm) hard
      tissue HydroKinetic(tm) laser system is unprecedented.
      Market reception is strong. We are establishing very key
      relationships and, most significantly, realizing revenue with a
      big increase in current month shipments."

      What
      do you think "very key relationships" means? What
      other than one or (relationship*s*) more distributors
      can be meant? And what do you say to "*big* increase
      in current month shipments" or "Market reception is
      strong"? I see my expectations have been pretty much
      correct. And this is just the beginning. Watch out for
      additional press releases on LaserSmile retail sales
      channel, LaserToner marketing start, and maybe even
      DermaLase announcements.

      Here we
      go!

      Amiga2000C

    • Your assessment is correct. Premier is cutting
      price because the market demands that; they are trying
      to find price level where product will sell. Bad
      news for BLTI. They will have to match price or go
      lower to sell anything. Stock still over valued.

    • View More Messages
 
BIOL
2.19-0.01(-0.45%)Aug 26 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.